** Shares of Gain Therapeutics GANX.O down ~18% to $1.40 in extended trading on planned equity raise
** Bethesda, Maryland-based firm announces offering of stock and warrants
** It expects to use net offering proceeds to continue clinical/nonclinical development of its lead product candidate GT-02287 for treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease
** Newbridge Securities sole bookrunner for offering
** GANX on Tues closed down 8.6% at $1.70, down 21% YTD
** As of May 31, co had ~30.1 mln shares outstanding, per the prospectus
** All 7 analysts covering GANX are bullish and median PT is $8, latest LSEG data reflects
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.